天坛生物：成都蓉生药业获药品GMP符合性检查告知书

Core Viewpoint - TianTan Biological announced that its subsidiary Chengdu Rongsheng Pharmaceutical has received the GMP compliance inspection notice and the updated drug production license from the Sichuan Provincial Drug Administration, allowing for an expansion in the production scale of "Recombinant Human Coagulation Factor VIII" [1] Group 1 - Chengdu Rongsheng has completed the site change for the production of "Recombinant Human Coagulation Factor VIII" [1] - The GMP compliance inspection was conducted from August 18 to August 21, 2025, and concluded that the company meets the relevant regulations [1] - The updated drug production license allows for the production of therapeutic biological products (Recombinant Human Coagulation Factor VIII) at the new address in Chengdu, Sichuan Province [1]